Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02327-17. doi: 10.1128/AAC.02327-17. Print 2018 Apr.

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.

Author information

1
JMI Laboratories, North Liberty, Iowa, USA.
2
University of Iowa, Iowa City, Iowa, USA.
3
JMI Laboratories, North Liberty, Iowa, USA michael-huband@jmilabs.com.

Abstract

Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active against Staphylococcus aureus (MIC50/MIC90, 0.12/0.25 mg/liter), including methicillin-resistant S. aureus (MRSA); streptococci (MIC50/MIC90, 0.06/0.12 mg/liter), including Streptococcus pneumoniae, viridans group streptococci, and beta-hemolytic streptococci; Enterobacteriaceae, including Escherichia coli (MIC50/MIC90, 0.5/2 mg/liter); Haemophilus influenzae (MIC50/MIC90, 1/1 mg/liter); and Moraxella catarrhalis (MIC50/MIC90, 0.25/0.25 mg/liter). Omadacycline merits further study in serious infections where resistant pathogens may be encountered.

KEYWORDS:

omadacycline

PMID:
29378719
PMCID:
PMC5913935
DOI:
10.1128/AAC.02327-17
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center